Immune response in addicts with chronic hepatitis C treated with interferon and ribavirine

An inefficient immune response against the hepatitis C virus (HCV), combined with viral evasion mechanisms, is responsible for the chronicity of infection. The need to evaluate the innate mechanisms of the immune response, such as TLR3 and IFN-λ3, and their relationship with the virus–host interaction is important for understanding the pathogenesis of chronic hepatitis C. The present study aimed to investigate the gene expressions of TRL3 and IFNL3 in liver tissue, seeking to evaluate whether these could be potential biomarkers of HCV infection. A total of 23 liver biopsy samples were collected from patients with chronic HCV, and 8 biopsies were collected from healthy control patients. RNA extraction, reverse transcription and qPCR were performed to quantify the relative gene expressions of TLR3 and IFNL3. Data on the viral load; AST, ALT, GGT and AFP levels; and the viral genotype were collected from the patients′ medical records. The intrahepatic expression of TLR3 (p = 0.0326) was higher in chronic HCV carriers than in the control group, and the expression of IFNL3 (p = 0.0037) was lower in chronic HCV carriers than in the healthy control group. The expression levels of TLR3 (p = 0.0030) and IFNL3 (p = 0.0036) were higher in the early stages of fibrosis and of necroinflammatory activity in the liver; in contrast, TLR3 and IFNL3 expressions were lower in the more advanced stages of fibrosis and inflammation. There was no correlation between the gene expression and the serum viral load. Regarding the initial METAVIR scale scores, liver transaminase levels were lower in patients with advanced fibrosis when correlated with TLR3 and IFNL3 gene expressions. The results suggest that in the early stages of the development of hepatic fibrosis, TLR3 and IFN-λ3 play important roles in the antiviral response and in the modulation of the tolerogenic liver environment because there is a decrease in the intrahepatic expressions of TLR3 and IFNL3 in the advanced stages of fibrosis, probably due to viral evasion mechanisms.

Download Full-text

Newer molecules and new hopes in the management of chronic hepatitis C

JMS SKIMS ◽

10.33883/jms.v13i2.45 ◽

2010 ◽

Vol 13 (2) ◽

pp. 39-40

Author(s):

Showkat Ali Zargar

Keyword(s):

Hepatocellular Carcinoma ◽

Immune Response ◽

Liver Transplantation ◽

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Chronic Infection ◽

Antiviral Therapies ◽

Chronic Hcv Infection ◽

Chronic Hcv

Chronic hepatitis C is highly prevalent with prevalence rate of around 3% involving about 180 million people worldwide, despite major advances in its understanding of viral 1 pathogenesis and significant evolution in antiviral therapies. Most of the patients develop chronic infection because the virus evades the host immune response in majority of patients. Chronic HCV infection can lead to cirrhosis and hepatocellular carcinoma. Complications of HCV-related cirrhosis are the leading indication for liver transplantation in United States and Europe...... J Med Sci 2010;13(2): 39-40.

Download Full-text

Host immune response in chronic hepatitis C infection: involvement of cytokines and inflammasomes

Romanian Journal of Morphology and Embryology ◽

10.47162/rjme.61.1.04 ◽

2020 ◽

Vol 61 (1) ◽

pp. 33-43

Author(s):

Mihail Virgil Boldeanu ◽

◽

Isabela Siloşi ◽

Andreea Lili Bărbulescu ◽

Raluca Elena Sandu ◽

...

Keyword(s):

Immune Response ◽

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Host Immune Response ◽

Hepatitis C Infection

Download Full-text

1(OH)VitD3 Supplementation Could Enhance Th1 Immune Response During Interferon-Free Treatment for Chronic Hepatitis C Patients

The American Journal of Gastroenterology ◽

10.14309/00000434-201510001-02037 ◽

2015 ◽

Vol 110 ◽

pp. S858-S859

Author(s):

Yasuteru Kondo ◽

Tatsuki Morosawa ◽

Yasuyuki Fujisaka ◽

Teruyuki Umetsu ◽

Jun Inoue ◽

...

Keyword(s):

Immune Response ◽

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Free Treatment ◽

Chronic Hepatitis C Patients ◽

Th1 Immune Response

Download Full-text

Double Filtration Plasmapheresis Could Induce a Favorable Immune Response for Chronic Hepatitis C Therapy

Therapeutic Apheresis and Dialysis ◽

10.1111/j.1744-9987.2012.01113.x ◽

2012 ◽

Vol 16 (5) ◽

pp. 478-479 ◽

Cited By ~ 1

Author(s):

Yasuteru Kondo ◽

Yoshiyuki Ueno ◽

Tooru Shimosegawa

Keyword(s):

Immune Response ◽

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Double Filtration Plasmapheresis ◽

Hepatitis C Therapy ◽

Double Filtration

Download Full-text

Low response rates to hepatitis B vaccine in patients with chronic hepatitis C

International Journal of Community Medicine and Public Health ◽

10.18203/2394-6040.ijcmph20214248 ◽

2021 ◽

Vol 8 (11) ◽

pp. 5189

Author(s):

Cláudia Alexandra Pontes Ivantes ◽

Tiago Zibetti Dos Passos ◽

João Marcelo Marchi Moraes ◽

Nicole Espindula Mattar ◽

Tereza Reck ◽

...

Keyword(s):

Immune Response ◽

Chronic Hepatitis ◽

Hepatitis C ◽

Hepatitis B ◽

Chronic Hepatitis C ◽

Smoking Status ◽

Response Rates ◽

Vaccine Response ◽

Genotype 3 ◽

Hbv Vaccine

Background: Hepatitis B is an infectious disease with converging routes of transmission with hepatitis C, making vaccination important in hepatitis C infected people. The objective was to evaluate the vaccine response against hepatitis B virus (HBV) in patients with chronic hepatitis C virus (HCV).Methods: Retrospective observational study was conducted between November 2018 and April 2020. Subjects with anti-HBs levels ≥10 mUI/ml were considered protected against HBV and those with chronic HCV who did not receive at least one dose of the vaccine schedule or with anti-HBc reagent or even with anti-HBs positive prior to the first dose documented in the HBV vaccine record were excluded. The immune response rates to VHB vaccine in patients with HCV was obtained and different variables were analysed.Results: The study group was compound of 370 subjects. The majority (55.7%) were male, with a median age of 55.6±11 years. Regarding present or past smoking, 56.9% of patients reported that were active or past tobacco users. HCV genotype 1 corresponded to 59.7% of the cases, followed by genotype 3 (36.88%). One hundred and fourteen (30.9%) of the patients had liver cirrhosis. The immune response to complete HBV vaccine was 62.3%, whereas the response to a single dose was 57.1% (p=1). Only the age of the patient at first dose (p=0.030), smoking status (p=0.017) and the presence of cirrhosis (p=0.046) influenced the immune response to HBV vaccine.Conclusions: The rate of immune response to standard schedule of HBV vaccination in patients with HCV was low (62.3%).

Download Full-text